Pfizer touts inhaled insulin

Pfizer is touting new clinical trial data that shows its inhaled version of insulin -- Exubera -- works just as well as the injectable kind and was well tolerated by patients over a period of two years. The results were released at a meeting of the American Diabetes Association. Pfizer believes that an inhaled version of insulin will offer higher compliance rates. Pfizer is developing the experimental drug with Sanofi-Aventis and Nektar Therapeutics. The FDA is expected to take action on their drug application by October.

- read this article from TheStreet.com for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.